Genentech R&D honcho heads to Rockefeller U.

Genentech's No. 2 R&D exec--Marc Tessier-Lavigne--is leaving his post to take the helm at Rockefeller University, home to some of the world's premier biomedical researchers. Tessier-Lavigne's move to become the first person from the biopharma industry to be named president of Rockefeller--a prestigious position by any standard--inevitably triggered fresh questions from the New York Times' Andrew Pollack about the brain drain from Genentech in the wake of the Roche takeover. But Tessier-Lavigne says he wasn't fleeing Roche management. "Of the top leadership in research, I'm the first person to leave and it has nothing to do with the merger," he tells the Times. "I wasn't looking to move away. In fact, this is probably the only job that could have lured me away from Genentech." Rockefeller release |  Story

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.